| Study | Reason for exclusion |
|---|---|
| Ahmed RJ, Gafni A, Hutton EK, Hu ZJ, Pullenayegum E, Von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez JJ, Ganzevoort W, Helewa M, Lee SK, Lee T, Logan AG, Moutquin JM, Singer J, Thornton JG, Welch R, Magee LA. The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension 68(4):1049-1055. 2016 | Not cost-effectiveness analysis. Costs consider Canadian healthcare system and are therefore of limited relevance to UK setting. |
| Barton JR, Istwan NB, Rhea D, Collins A, Stanziano GJ. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 9(4):236-41. 2006 | Not cost-effectiveness analysis. Costs considered reflect US healthcare setting therefore of limited relevance to UK. |
| Caughey AB, Sundaram V, Kaimal AJ, Cheng YW, Gienger A, Little SE, Lee JF, Wong L, Shaffer BL, Tran SH, Padula A, McDonald KM, Long EF, Owens DK, Bravata DM. Maternal and neonatal outcomes of elective induction of labor. Evidence report/technology assessment (176) 1-257. 2009 | Not specific to women with chronic hypertension |
| Lai J, Niu B, Caughey AB. A cost-effectiveness analysis on the optimal timing of delivery for women with preeclampsia without severe features. American Journal of Obstetrics and Gynecology, 214(1):S237-S238 2016 | Different population - women with pre-eclampsia |
| Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, Van der Post JA, Leeflang MM, Barton PM, Hyde CJ, Gupta JK, Khan KS. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess;12(6). 2008 | Not specific to women with chronic hypertension. |
| Meertens LJE, Scheepers HCJ, Willemse JPMM, Spaanderman MEA, Smits LJM. Should women be advised to use calcium supplements during pregnancy? A decision analysis. Matern Child Nutr 14:e12479. 2018 | Not specific to women with chronic hypertension |
| Merrill M, Aviram A, Niu B, Kuo K, Caughey AB. Tight versus less tight control of blood pressure in pregnant women with chronic hypertension - a cost-effective analysis. American Journal of Obstetrics & Gynecology 214(1):S406-S407 2016 | Available as abstract only (conference poster) |
| O’Mahony JF, Mone F, Tyrrell E, Mulcahy C, McParland P, Breathnach F, Morrison JJ, Higgins J, Daly S, Cotter A, Hunter A, Dicker P, Tully E, Malone FD, Normand C, McAuliffe FM. The cost effectiveness of a policy of universal aspirin versus aspirin indicated by a positive pre-eclampsia screening test. American Journal of Obstetrics & Gynecology 216(1): S483 2017 2016 | Not specific to women with chronic hypertension. |
| Rogozinska E, Marlin N, Jackson L, Rayanagoudar G, Ruifrok AE, Dodds J, Molyneaux E, van Poppel MNM, Poston L, Vinter CA, McAuliffe F, Dodd JM, Owens J, Barakat R, Perales M, Cecatti JG, Surita F, Yeo SA, Bogaerts A, Devlieger R, Teede H, Harrison C, Haakstad L, Shen GX, Shub A, El Beltagy N, Motahari N, Khoury J, Tonstad S, Luoto R, Kinnunen TI, Guelfi K, Facchinetti F, Petrella E, Phelan S, Scudeller TT, Rauh K, Hauner H, Renault K, de Groot CJM, Sagedal LR, Vistad I, Stafne SN, Morkved S, Salvesen KA, Jensen DM, Vitolo M, Astrup A, Geiker NRW, Kerry S, Barton P, Roberts T, Riley RD, Coomarasamy A, Mol BW, Khan KS, Thangaratinam S. Effects of antenatal diet and physical activity on maternal and fetal outcomes: individual patient data meta-analysis and health economic evaluation. Health Technol Assess;21(41) 2017 | Not specific to chronic hypertension |
| van Baaren G‐J, Broekhuijsen K, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, Oudijk MA, Bloemenkamp KWM, Scheepers HCJ, Bremer HA, Rijnders RJP, van Loon AJ, Perquin DAM, Sporken JMJ, Papatsonis DNM, van Huizen ME, Vredevoogd CB, Brons JTJ, Kaplan M, van Kaam AH, Groen H, Porath M, van den Berg PP, Mol BWJ, Franssen MTM, Langenveld J, for the HYPITAT‐II Study Group. An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT‐II). BJOG 2017;124:453–461 2017 | Not cost-utility analysis. Costs considered reflect US healthcare setting therefore of limited relevance to UK. |
| Vijgen S, Koopmans C, Opmeer B, Groen H, Bijlenga D, Aarnoudse J, Bekedam D, van den Berg P, de Boer K, Burggraaff J, Bloemenkamp K, Drogtrop A, Franx A, de Groot C, Huisjes A, Kwee A, van Loon A, Lub A, Papatsonis D, van der Post J, Roumen F, Scheepers H, Stigter R, Willekes C, Mol B, Van Pampus M. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial). BJOG, 117: 1577-1585. 2010 | Not specific to women with chronic hypertension |
| Vogel SA, Rajaii R, Ottaviano G, Kim L, Yeaton-Massey A, Caughey AB. Low-dose aspirin for prevention of pre-eclampsia and its complications: a cost-effectiveness analysis. Archives of Disease in Childhood - Fetal and Neonatal Edition;95:Fa46. 2010 | Not specific to women with chronic hypertension. |
| Werner EF, Hauspurg AK, Rouse DJ. A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States. Obstet Gynecol 126(6):1242-50 2015 | Not specific to women with chronic hypertension |
| Yeaton-Massey A, Ohno M, Caughey A. Optimal delivery timing for mild gestational hypertension: a decision analysis. American Journal of Obstetrics & Gynecology 210(1): S192 2014 | Different population - mild gestational hypertension not chronic hypertension. |
From: Evidence review for interventions for chronic hypertension
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.